Unoprostone is a prostaglandin analogue used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are clinically unresponsive to other ocular antihypertensive agents. Ophthalmic Solution 0.15% is a synthetic docosanoid.
- Mechanism
- Curator reviewed
Unoprostone is believed to reduce elevated intraocular pressure (IOP), by increasing the outflow of aqueous humor. The mechanism of action for the IOP-lowering effect of unoprostone is controversial. Early studies showed that unoprostone increases aqueous humor outflow through the uveoscleral pathway similar to the 20-carbon prostaglandin analogs, such as latanoprost.8 More recent evidence, however, shows that it may work, at least in part, through stimulation of Ca2+-activated BK and CIC-2 type channels, leading to increased trabecular meshwork outflow.
- Primary indication
- For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements...Curator reviewed · 2 structured indications
- Formula / weight
- C22H38O5 · 382.541 g/mol (avg)
- First approval
- Canada, 2002 · United States, 2013
- Code names
- UF-021
Resolves to
TVHAZVBUYQMHBC-SNHXEXRGSA-NSMILESCCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Unoprostone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account